ClinicalTrials.gg
Active, not recruitingNCT07299084Updated May 19, 2026

A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus

A Phase 1 interventional study of Tirzepatide in Diabetes Mellitus, Type 2, Overweight and Obesity, sponsored by Eli Lilly and Company. Active, not recruiting at 1 site in Singapore. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Planned enrollment
39th of 43
40 · median 160
Started
2026
with 2 others
Phase 1
8 of 43
none open now
Primary completion
2026-11
later than 7 of 12 live
Registered
39th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 39th largest by planned enrollment, is one of 3 that started in 2026, is one of 8 in phase 1, reaches primary completion later than 7 of the 12 other live ones, and was the 39th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how fasting and stopping the use of tirzepatide affects the amount of food and drink that stays in the stomach after a meal. Ultrasound will be used to check the stomach content after a test meal.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Overweight
  • Obesity

Keywords

  • Point of Care Ultrasound (POCUS)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet one of the following criteria:

    • Have type 2 diabetes
    • Have obesity
    • Have overweight with at least one health issue related to weight but without type 2 diabetes

Exclusion criteria

Exclusion Criteria:

  • Have a condition that affects how their stomach empties
  • Have had weight loss surgery
  • Have type 1 diabetes
  • Have any major medical conditions or histories that could interfere with the study
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Participants with Type 2 Diabetes

    Participants will receive tirzepatide subcutaneously (SC)

    Drug: Tirzepatide

  • Experimental
    Participants with Overweight or Obesity Without Type 2 Diabetes

    Participants will receive tirzepatide SC

    Drug: Tirzepatide

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Lack of Gastric Content Retention Post-Solid Test Meal

    Time frame: Baseline, Day 171 (at 6, 8, 12, 18 and 24 hours after baseline or Day 170 solid test meal)

Secondary outcomes

  1. Percentage of Participants with Lack of Gastric Content Retention Post-Liquid Test Meal

    Time frame: Day 178 (at 6, 8, 12, 18 and 24 hours after Day 177 liquid test meal)

  2. Amount of Gastric Content Volume Post-Liquid Test Meal

    Time frame: Day 178 (at 6, 8, 12, 18 and 24 hours after Day 177 liquid test meal)

  3. Amount of Gastric Content Volume Post-Solid Test Meal

    Time frame: Baseline, Day 171 (at 6, 8, 12, 18 and 24 hours after baseline or Day 170 solid test meal)

  4. Percentage of Participants with Lack of Gastric Content Retention Post-Solid Test Meal After Discontinuation of Tirzepatide

    Time frame: Baseline through 8 days after discontinuation of tirzepatide at 6, 8, 12,18 and 24 hours

  5. Percentage of Participants with Grades 0, 1, and 2 from Antrum Grading Scale Post-Solid Test Meal

    Time frame: Baseline, Day 171 (at 6, 8, 12, 18 and 24 hours after baseline or Day 170 solid test meal)

  6. Percentage of Participants with Grades 0, 1, and 2 from Antrum Grading Scale Post-Liquid Test Meal

    Time frame: Day 178 (at 6, 8, 12, 18 and 24 hours after Day 177 liquid test meal)]

  7. Percentage of Participants with Grades 0, 1, and 2 from Antrum Grading Scale After Discontinuation of Tirzepatide

    Time frame: Baseline through 8 days after discontinuation of tirzepatide at 6, 8, 12,18 and 24 hours

07

Study locations

1 site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 10 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 23, 2025
StartActual
Jan 14, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07299084
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Jan 14, 2026
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
May 19, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion